The goal of this nano immunotherapy combination is to increase the potency of immune checkpoint inhibitors, a class of immunotherapy that elicits dramatic benefits in only a modest subset of cancer patients, to a significantly larger proportion of patients. because A team from the George Washington University (GW) Cancer Center has engineered nano immunotherapy that combines the advantages of nanotechnology and immunotherapy to treat cancer.

Health Sciences

Rohan Fernandes; Ph.D., assistant professor of medicine at the GW School of Medicine and Health Sciences; received more than $1.6 million from the National Institutes of Health for the study. The grant is an R37 award; which is a MERIT — Method to Extend Research in Time — Award for early-stage investigators to give them the flexibility and opportunity for creativity and innovation; as well as; additional time to successfully launch their careers.

The researchers will work with Prussian blue nanoparticles (PBNPs) coated with immunological signals; used in combination with checkpoint inhibitors. Prussian blue is a mixe valence; an inorganic nanoparticle that has been historically using as a dark blue pigment. because It exhibits unique electrical, optical, and magnetic properties; which make Prussian blue a candidate for several biological; medicinal; and other applications, including photothermal therapy.

Tumor eradication

“We believe that the ensemble approach to targeting tumor cells and neighboring immune cells using PBNPs hold the key in converting non-responsive; immunologically ‘cold’ tumors into responsive ‘hot’ tumors;” Fernandes said. because After elucidating the effects of PBNPs used for photothermal therapy on the tumor and adjacent immune cells; Fernandes will test the efficacy of the ensemble nano immunotherapy on tumor eradication and relapse prevention and will evaluate the success of nano immunotherapy in treating disseminated cancer.

“If we are successful, this study will provide an impetus for clinical translation of our nano immunotherapy,” said Fernandes. “We could then achieve our goal of extending lasting benefits to a larger population of cancer patients.” The researchers will work with Prussian blue nanoparticles (PBNPs) coated with immunological signals; used in combination with checkpoint inhibitors.

Photothermal therapy.

Prussian blue is a mixe valence; an inorganic nanoparticle that has been historically used as a dark blue pigment. because It exhibits unique electrical; optical; and magnetic properties, which make Prussian blue a candidate for several biological; medicinal, because and other applications, including photothermal therapy. Because “We believe that the ensemble approach to targeting tumor cells and neighboring immune cells using PBNPs hold the key in converting non-responsive; immunologically ‘cold’ tumors into responsive ‘hot’ tumors;” Fernandes said.
After elucidating the effects of PBNPs used for photothermal therapy on the tumor and adjacent immune cells, Fernandes will test the efficacy of the ensemble nano immunotherapy on tumor eradication and relapse prevention and will evaluate the success of nano immunotherapy in treating disseminate cancer. because “If we are successful; this study is providing an impetus for clinical translation of our nano immunotherapy;” said Fernandes. because “We could then achieve our goal of extending lasting benefits to a larger population of cancer patients.”